Accelerate the Startup of Your Clinical Trials Without Sacrificing Quality: Common Pitfalls that Cause Delays and How to Avoid Them
A Free CenterWatch On-Demand Webinar | Sponsored by Diligent Pharma, LLC
Time is money, especially when it comes to drug development and delays initiating clinical trials are common.
The introduction of new technologies and decentralized approaches has led to more partners and intermediary companies becoming involved. This proliferation of companies involved in clinical trials has introduced new challenges and research shows timelines are getting longer, particularly when it comes to qualifying new providers of clinical trial services.
The Tufts/Avoca benchmarking study on industry qualification practices estimated that the clinical research industry spends $130-$150 million each year on assessments to qualify new providers of clinical trial services. New-provider qualifications typically take 17 weeks from request for information (RFI) initiation to contract for single-service providers and 23 weeks for multi-service.
Ken Getz, Director and Research Professor of the Tufts Center for the Study of Drug Development (CSDD), and Jay Turpen, Head of Client Services at Diligent Pharma, will explain insights gleaned from Tufts’ industry research as well as Operation Warp Speed that accelerated vaccines and treatment for COVID-19. They’ll share how you can scale and incorporate these techniques to improve your cycle times. Furthermore, they will discuss an innovative solution that includes leveraging vendor qualification assessments to save time and resources for trial sponsors as well as clinical trial service providers.
- An overview of current clinical trial performance, including common pitfalls that impact startup cycle times in clinical research
- How to address some of the startup cycle time challenges — without sacrificing quality
- How to turn those key pitfalls into opportunities for improvement using an innovative solution which leverages the results of vendor qualification to reduce cycle times and resources in trial initiation
It’s widely reported that a single day lost in a drug launch has a lifetime cost of $6 million. Can you afford to lose even one moment? Accelerate your clinical trials with this free webinar. Join us by registering today.
Who Will Benefit:
- Clinical operations professionals at sponsors and CROs
- Contracting, procurement or outsourcing directors
- Quality control and regulatory professionals
- Operations, contracts and business development leaders at providers of clinical trial services or technologies
- Directors and Vice Presidents
- C-suite professionals
Meet Your PresenterS:
Director and Professor
Tufts Center for the Study of Drug Development, Tufts University School of Medicine
Ken Getz, is the Director and a professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, where he conducts grant-funded research on pharmaceutical R&D management and execution; protocol design optimization, contract service provider and investigative site management, e-clinical technology and data usage and patient engagement.
A well-known speaker at conferences, symposia, universities, investor meetings and corporations, Ken has published extensively in peer-review journals, books and in the trade press and writes a bi-monthly column nominated for a Neal Award in Applied Clinical Trials. Ken holds a number of board appointments in the private and public sectors and serves on the editorial boards of Pharmaceutical Medicine and Therapeutic Innovation and Regulatory Science.
Ken is the founder of CenterWatch, a leading publisher in the clinical trials industry, and one of several businesses that he has created and sold. He is also the chairman of CISCRP – a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise.
Head of Client Services
Diligent Pharma, LLC
Jay Turpen is Head of Client Services at Diligent Pharma, LLC, where he leads a team of staff and auditors that implement a risk-based qualification service for clients. He has been in the pharmaceutical industry for 32 years and has held various leadership roles. He has a wealth of experience in GMP, GLP and GCP environments, with significant real-life experience in developing numerous new drug candidates.